<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02382380</url>
  </required_header>
  <id_info>
    <org_study_id>206338</org_study_id>
    <nct_id>NCT02382380</nct_id>
  </id_info>
  <brief_title>Evaluation of Gadoterate in Patients With Decreased Kidney Function</brief_title>
  <official_title>Evaluation of Gadoterate in Patients With Renal Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guerbet</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Loyola University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is for individuals with decreased kidney function whose doctor has ordered
      Magnetic Resonance Imaging (MRI). Because kidney function is decreased, these patients
      usually do not receive the intravenous contrast material that can improve the accuracy of the
      MRI findings. The purpose of this study is to evaluate the safety and benefit of using a
      contrast material called Gadoterate in patients with decreased kidney function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gadolinium-based intravenous contrast agents are widely used for the enhancement of MRI
      findings. However, these agents have been implicated in varying degrees of nephrotoxicity and
      therefore are not usually used in patients with renal dysfunction. Gadoterate is a Gadolinium
      agent and previous studies have indicated that it is safe in patients with decreased kidney
      function. The purpose of this study is to evaluate the safety and efficacy of using
      Gadoterate in this patient population.

      Participants who have been scheduled for an MRI will choose to either receive Gadoterate
      contrast as part of their MRI or not receive Gadoterate as part of their MRI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in glomerular filtration rate (GFR)</measure>
    <time_frame>6 months</time_frame>
    <description>Change in GFR from 0 to 6 months</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Renal Dysfunction</condition>
  <arm_group>
    <arm_group_label>Gadoterate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who choose to receive Gadoterate will receive an MRI exam with standard pre-contrast and Gadoterate-enhanced acquisitions (0.2 mL/kg). The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Gadoterate</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who choose not to receive Gadoterate will receive an MRI exam with no Gadolinium contrast. MRI protocols utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadoterate</intervention_name>
    <description>Patients who choose to receive Gadoterate will receive an MRI exam with standard pre-contrast and Gadoterate-enhanced acquisitions (0.2 mL/kg). The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).</description>
    <arm_group_label>Gadoterate</arm_group_label>
    <other_name>Dotarem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Gadoterate</intervention_name>
    <description>Patients who choose not to receive Gadoterate will receive an MRI exam with no Gadolinium contrast. The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).</description>
    <arm_group_label>No Gadoterate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Glomerular filtration rates (GFR) less than 30 ml/min but not on dialysis

          -  Being sent for an MRI examination in the course of routine clinical evaluation of one
             of the following indications: suspected or known head/neck/brain mass, hepatic mass,
             renal mass, pancreatic mass, or prostate mass, as well as evaluation of carotid or
             abdominopelvic vasculature.

        Exclusion Criteria:

          -  Pregnant and lactating females

          -  Planned initiation of chemotherapy or surgery within 72 hours of the MRI exam

          -  Hemodynamic instability or acute coronary syndrome

          -  History of nephrotoxic medication within 2 weeks of the exam

          -  Less than 18 years old

          -  Known decrease in GFR (within past 3 months) of more than 20%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ari Goldberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loyola University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ari Goldberg, MD</last_name>
    <phone>708-216-2229</phone>
    <email>argoldberg@lumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari Goldberg, MD</last_name>
      <phone>708-216-2229</phone>
      <email>argoldberg@lumc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Thomsen HS. Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide. Eur Radiol. 2006 Dec;16(12):2619-21. Epub 2006 Oct 24.</citation>
    <PMID>17061066</PMID>
  </reference>
  <reference>
    <citation>Sam AD 2nd, Morasch MD, Collins J, Song G, Chen R, Pereles FS. Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg. 2003 Aug;38(2):313-8.</citation>
    <PMID>12891113</PMID>
  </reference>
  <reference>
    <citation>Perazella MA. Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephrol. 2009 Feb;4(2):461-9. doi: 10.2215/CJN.06011108. Review. Erratum in: Clin J Am Soc Nephrol. 2009 Apr;4(4):866.</citation>
    <PMID>19201920</PMID>
  </reference>
  <reference>
    <citation>Janus N, Launay-Vacher V, Karie S, Clement O, Ledneva E, Frances C, Choukroun G, Deray G. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. Eur J Radiol. 2010 Feb;73(2):357-9. doi: 10.1016/j.ejrad.2008.11.021. Epub 2009 Jan 6.</citation>
    <PMID>19128909</PMID>
  </reference>
  <reference>
    <citation>Port M, Id√©e JM, Medina C, Robic C, Sabatou M, Corot C. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals. 2008 Aug;21(4):469-90. doi: 10.1007/s10534-008-9135-x. Epub 2008 Mar 15.</citation>
    <PMID>18344005</PMID>
  </reference>
  <reference>
    <citation>Laurent S, Elst LV, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging. 2006 May-Jun;1(3):128-37.</citation>
    <PMID>17193689</PMID>
  </reference>
  <reference>
    <citation>Deray G, Rouviere O, Bacigalupo L, Maes B, Hannedouche T, Vrtovsnik F, Rigothier C, Billiouw JM, Campioni P, Ferreiros J, Devos D, Alison D, Glowacki F, Boffa JJ, Marti-Bonmati L. Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study). Eur Radiol. 2013 May;23(5):1250-9. doi: 10.1007/s00330-012-2705-x. Epub 2012 Dec 5.</citation>
    <PMID>23212275</PMID>
  </reference>
  <reference>
    <citation>Maurer M, Heine O, Wolf M, Durmus T, Wagner M, Hamm B. Tolerability and diagnostic value of gadoteric acid in the general population and in patients with risk factors: results in more than 84,000 patients. Eur J Radiol. 2012 May;81(5):885-90. doi: 10.1016/j.ejrad.2011.04.022. Epub 2011 May 8.</citation>
    <PMID>21555197</PMID>
  </reference>
  <reference>
    <citation>Herborn CU, Honold E, Wolf M, Kemper J, Kinner S, Adam G, Barkhausen J. Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Invest Radiol. 2007 Jan;42(1):58-62.</citation>
    <PMID>17213750</PMID>
  </reference>
  <reference>
    <citation>Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol. 2007 Feb;188(2):586-92.</citation>
    <PMID>17242272</PMID>
  </reference>
  <reference>
    <citation>Lencioni R, de Baere T, Burrel M, Caridi JG, Lammer J, Malagari K, Martin RC, O'Grady E, Real MI, Vogl TJ, Watkinson A, Geschwind JF. Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol. 2012 Oct;35(5):980-5. Epub 2011 Oct 19. Review.</citation>
    <PMID>22009576</PMID>
  </reference>
  <reference>
    <citation>Lima XT, Alora-Palli MB, Kimball AB, Kay J. Validation of a screening instrument for nephrogenic systemic fibrosis. Arthritis Care Res (Hoboken). 2013 Apr;65(4):637-42. doi: 10.1002/acr.21877.</citation>
    <PMID>23097320</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2015</study_first_submitted>
  <study_first_submitted_qc>March 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2015</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loyola University</investigator_affiliation>
    <investigator_full_name>Ari Goldberg</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Contrast Agent</keyword>
  <keyword>Gadoterate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
    <mesh_term>Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

